OSE Immunotherapeutics SA ORPOF
4.43 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
Day range unavailable
4.43 52-week range 11.60
- YTD
- -61.81%
- 1 year
- -61.81%
- Market cap
- 109.52M
- EPS (ttm)
- -1.91
- YTD return
- -61.81%
- 1-year return
- -61.81%
- Previous close
- 4.43
- 52-week range
- 4.43 – 11.60
1Y -7.17 (-61.81%)
News
OSE Immunotherapeutics SA (ORPOF) Lusvertikimab Mechanism and Clinical Progress in Ulcerative Colitis and Chronic Pouchitis Transcript 
OSE Immunotherapeutics SA (ORPOF) Discussion of Tedopi Immunotherapy Pipeline and Clinical Progress Across Oncology Indications Transcript 
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document 
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing 
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer 
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position 
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients 
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting 
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting 
OSE Immunotherapeutics Evolves its Leadership Team
Your note
Sign in to keep a note on ORPOF — it syncs with the Stock Master app.